Novartis Anti-Bribery Report is “Substantively Meaningless”
Mike Koehler notes that Novartis is a repeat FCPA offender, having settled a $25 million FCPA enforcement action in 2016 concerning conduct in China, and $347 million FCPA enforcement action in 2020 concerning conduct in Greece, Vietnam, and South Korea.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.